Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) fell 3.8% during mid-day trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares traded hands during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The business has a 50-day moving average price of C$10.60 and a 200-day moving average price of C$10.60. The firm has a market capitalization of C$168.68 million and a price-to-earnings ratio of -28.19. The company has a quick ratio of 128.68, a current ratio of 129.63 and a debt-to-equity ratio of 0.05.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 4/22 – 4/26
- Insider Buying Explained: What Investors Need to Know
- 3 Stocks Leading the U.S. Agriculture Comeback
- Trading Stocks: RSI and Why it’s Useful
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
